Barrick Mining Corporation Stock Price, News & Analysis

Barrick Mining (NYSE:B) has announced that its Fourmile project in Nevada is emerging as one of the century's most significant gold discoveries. The updated preliminary economic assessment (PEA) reveals potential for annual gold production of 600-750,000 ounces at mining rates of 1.5-1.8Mt per year.

The project boasts exceptional characteristics including high-grade resources of 3.6Mt @ 11.8g/t for 1.4Moz (M&I) and 14Mt @ 14.1g/t for 6.4Moz (Inferred), with exploration upside potential of 32-34Mt @ 15-16g/t. The project's preliminary economics indicate a mine life exceeding 25 years with projected AISC of $650-750/oz and estimated project capital of $1.5-1.7 billion.

Barrick Mining (NYSE:B) has announced the sale of its Hemlo Gold Mine in Canada to Carcetti Capital Corp. (to be renamed Hemlo Mining Corp.) for up to $1.09 billion. The deal structure includes $875 million in cash, $50 million in HMC shares, and potential additional payments of up to $165 million linked to production and gold prices starting January 2027.

HMC is led by experienced mining executive Robert Quartermain and backed by Wheaton Precious Metals and Orion Mine Finance Management. The transaction, expected to close in Q4 2025, is part of Barrick's strategy to focus on its Tier One gold and copper portfolio, with total proceeds from non-core asset sales expected to exceed $2 billion this year.

BioArctic (NASDAQ STOCKHOLM: BIOA B) announced that CEO Gunilla Osswald has been named Uppsala University's Alumnus of the Year 2025. The recognition highlights her exemplary leadership and contributions to scientific innovation, particularly in the development of lecanemab for Alzheimer's disease.

Earlier in March 2025, Osswald and BioArctic's founders were also awarded the university's Innovation and Entrepreneurship Prize. The university praised her visionary and inclusive leadership style, noting her ability to foster collaboration and serve as a role model for women in science and technology.

Integrum AB (INTEG B) unveiled its new global marketing strategy at the AOPA National Assembly in Orlando, introducing BondedMatrix™, a term describing the OPRA™ Implant System's unique capability to integrate soft tissue and bone. The strategy aims to better communicate the system's distinct advantages in bone-anchored prosthetics.

The OPRA™ Implant System, invented by Dr. Rickard Brånemark, has been refined since 1990 and has been used in over 1,000 implants worldwide. BondedMatrix™ specifically refers to the biologically integrated barrier connecting skin and bone at the penetration site, a unique feature achieved through OPRA's surgical technique and implant design.

BioArctic AB (Nasdaq Stockholm: BIOA B) announced that its partner Eisai has initiated a rolling submission of a Supplemental Biologics License Application (sBLA) to the FDA for Leqembi Iqlik's subcutaneous autoinjector as a weekly starting dose for early Alzheimer's disease treatment. This follows the recent approval of Leqembi Iqlik for maintenance dosing in the US on August 29, 2025.

If approved, Leqembi Iqlik would become the first anti-amyloid treatment offering at-home injection from start to maintenance. The proposed dosing regimen includes 500 mg SC dosing (two 250 mg injections) weekly, as an alternative to bi-weekly intravenous dosing. The autoinjector requires only 15 seconds per injection and could potentially reduce healthcare resources associated with IV administration.

Leqembi, currently approved in 48 countries and under review in 10 others, uniquely targets both amyloid plaque and protofibrils in Alzheimer's disease treatment.

Integrum AB (Nasdaq First North: INTEG B) has scheduled its first quarter 2025/26 results presentation for September 1, 2025, at 10:00 CET. The presentation will be conducted via webcast, featuring CEO Martin Hillsten and CFO Jörgen Svanström presenting the quarterly report in English.

The report and presentation materials will be accessible through the company's investor relations website and the Finwire.tv platform, where participants will have the opportunity to ask questions during the session.

Helzberg, a subsidiary of Berkshire Hathaway (NYSE:BRK), has announced a national partnership with Big Brothers Big Sisters of America (BBBSA) ahead of Big Brothers Big Sisters Month in September 2025. The collaboration combines financial investment, volunteer engagement, and career exploration opportunities to enhance youth mentorship nationwide.

The partnership launched in Kansas City with BBBSA's Diamond Anniversary celebration at Kauffman Stadium and will continue with various events including a special gathering at the KC Current match on August 30. Helzberg's nationwide network of associates will participate in volunteer efforts including career day mentoring and Pack + Give Back events across key markets.

BioArctic (Nasdaq Stockholm: BIOA B) has entered into a significant collaboration agreement with Novartis Pharma AG to develop potential neurodegeneration treatments using BioArctic's proprietary BrainTransporter technology. The deal includes an upfront payment of $30 million to BioArctic.

Under the agreement, BioArctic will develop a new drug candidate combining their BrainTransporter technology with Novartis' proprietary antibody. If Novartis exercises their option following evaluation, they could pay up to $772 million in additional milestone payments plus mid-single digit royalties on future global sales. This marks BioArctic's third partnership utilizing their BrainTransporter platform, which enhances brain uptake of therapeutic agents through blood-brain barrier biology.

BioArctic AB (NASDAQ Stockholm: BIOA B) announced the EU launch of Leqembi®, the first therapy targeting an underlying cause of Alzheimer's disease, starting in Austria on August 25, 2025, and Germany on September 1, 2025.

The drug, approved by the European Commission in April 2025, is indicated for adult patients with mild cognitive impairment and mild dementia due to early Alzheimer's disease who are ApoE ε4 non-carriers or heterozygotes with confirmed amyloid pathology. In clinical trials, Leqembi demonstrated a 31% reduction in clinical decline at 18 months compared to placebo in the EU indicated population.

The treatment uniquely targets both amyloid plaque and protofibrils, potentially impacting tau accumulation. Common adverse reactions include infusion-related reactions (26%), ARIA-H (13%), headache (11%), and ARIA-E (9%).